Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial

Reymen, Bart; Gisbergen, Marike W. van; Even, Aniek J.G.; Zegers, Catharina M.L.; Das, Marco; Vegt, Erik; Wildberger, Joachim E.; Mottaghy, Felix M.; Yaromina, Ala; Dubois, Ludwig; Elmpt, Wouter van; Ruysscher, Dirk De

doi:10.1016/j.ctro.2019.12.002

Cited by 13 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although side effects remained manageable (mainly represented by headache, commonly observed with vasodilator treatments), a dedicated phase III trial investigating NTG addition for 5 days with conventional first-line chemotherapy in advanced NSCLC patients was stopped at first interim analysis for non-significance [ 370 ]. Its combination with radiotherapy failed to demonstrate a clinical interest and no additional investigations are currently evaluated for this approach [ 371 ].…”

Section: Hypoxia-related Treatments and Research Developmentmentioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Secondly, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.

show abstract

Section: Hypoxia-related Treatments and Research Developmentmentioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Unfortunately, as accrual was still ongoing, the correlation between change in tumor hypoxia during treatment and the actual treatment outcome could not be assessed. Nevertheless and despite limited evidence, these results suggest that [18F]-HX4 PET can be used to monitor treatment response [20].…”

Section: Monitoring Treatment Response [18f]-hx4 Petmentioning

confidence: 87%

“…In line with these findings, [18F]-HX4 PET has been successfully used to determine treatment response to metformin, an antidiabetic drug with anticancer properties, in animal models of NSCLC and colorectal cancer [66]. In clinical setting, Reymen et al [20] assessed treatment response to nitroglycerin as a potential radiosensitizer using [18F]-HX4 in patients suffering from NSCLC. They found that administration of nitroglycerin did not result in the hypothesized decrease of tumor hypoxia defined as [18F]-HX4 uptake, more indicative of the arguable potential of nitroglycerin as a radiosensitizer.…”

Section: Monitoring Treatment Response [18f]-hx4 Petmentioning

confidence: 99%

“…Furthermore, tumoral baseline [18F]-HX4 uptake was positively correlated with tumor growth rate in a lung [65] and colorectal cancer xenograft model [66]. Only recently, Reymen et al were the first to report in a study of 42 NSCLC patients that the degree of tumoral [18F]-HX4 uptake was negatively correlated with prognosis [20].…”

Section: Prognostic Value Of Hypoxia Pet Imaging [18f]-hx4 Petmentioning

confidence: 99%

See 1 more Smart Citation

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer

Sanduleanu

Wiel

Lieverse

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Hypoxia—a common feature of the majority of solid tumors—is a negative prognostic factor, as it is associated with invasion, metastasis and therapy resistance. To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (PET). A plethora of hypoxia PET tracers, each with its own strengths and limitations, has been developed and successfully validated, thereby providing useful prognostic or predictive information. The current review focusses on [18F]-HX4, a promising next-generation hypoxia PET tracer. After a brief history of its development, we discuss and compare its characteristics with other hypoxia PET tracers and provide an update on its progression into the clinic. Lastly, we address the potential applications of assessing tumor hypoxia using [18F]-HX4, with a focus on improving patient-tailored therapies.

show abstract

“…This was thought to be due to a decreased hypoxic fraction however levels of hypoxia were not measured (Yasuda et al, 2006). A second phase II trial in NCLS combining nitroglycerin with chemo/ radiotherapy was stopped early when no reduction in tumour hypoxia or increased overall survival was seen (Reymen et al, 2020). The lack of overall survival was in part due to the heterogeneous treatment modalities and small sample size, but this cannot explain the lack of decreased hypoxia.…”

Section: Hypoxia Modificationmentioning

confidence: 99%

Manipulating the hypoxic tumour microenvironment to study therapy resistance

Ient

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial

Cited by 13 publications

References 33 publications

Hypoxia in Lung Cancer Management: A Translational Approach

Hypoxia in Lung Cancer Management: A Translational Approach

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer

Manipulating the hypoxic tumour microenvironment to study therapy resistance

Contact Info

Product

Resources

About